Pulse Biosciences, Inc.

Pulse Biosciences, Inc. company information, Employees & Contact Information

Pulse Biosciences is the inventor and sole proprietor of Nanosecond Pulsed Field Ablation™ (nsPFA™) technology. We are committed to health innovation that has the potential to improve and extend the lives of patients. Our proprietary Nanosecond Pulsed Field Ablation technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The people at Pulse Biosciences are some of the top experts in pulsed electric field technologies and have a broad range of engineering expertise across multiple medical device domains and will utilize nsPFA™ technology to treat a variety of applications for which an optimal solution remains unfulfilled. We have a deep and broad IP portfolio with over 130 issued patents globally owned and licensed. With this growing patent portfolio surrounding our innovative technology, Pulse Biosciences seeks to aggressively realize the potential of Nanosecond Pulsed Field Ablation technology by building a rich pipeline of transformative commercial applications.

Company Details

Employees
112
Founded
-
Address
Hayward, Ca, Us
Phone
650.697.3939
Industry
Medical Equipment Manufacturing
NAICS
Medical Equipment and Supplies Manufacturing
Surgical and Medical Instrument Manufacturing
Surgical Appliance and Supplies Manufacturing
Dental Equipment and Supplies Manufacturing
Ophthalmic Goods Manufacturing
Dental Laboratories
HQ
Hayward, CA
Looking for a particular Pulse Biosciences, Inc. employee's phone or email?

Pulse Biosciences, Inc. Questions

News

Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025 - Business Wire

Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025 Business Wire

Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study - Business Wire

Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study Business Wire

Pulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025 - FinancialContent

Pulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025 FinancialContent

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire

FDA Grants IDE Approval for nsPFA Cardiac Surgery System Study for Treating Atrial Fibrillation - Diagnostic and Interventional Cardiology

FDA Grants IDE Approval for nsPFA Cardiac Surgery System Study for Treating Atrial Fibrillation Diagnostic and Interventional Cardiology

Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer - Yahoo Finance

Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer Yahoo Finance

Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference - FinancialContent

Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference FinancialContent

Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results - Business Wire

Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results Business Wire

Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation (nsPFA) Cardiac Catheter - Diagnostic and Interventional Cardiology

Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation (nsPFA) Cardiac Catheter Diagnostic and Interventional Cardiology

Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results - Business Wire

Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results Business Wire

Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants - Business Wire

Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants Business Wire

Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference - FinancialContent

Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference FinancialContent

Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference - FinancialContent

Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference FinancialContent

Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - Business Wire

Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting Business Wire

Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study - Business Wire

Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study Business Wire

Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid - Business Wire

Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid Business Wire

Pulse Biosciences’ nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual Meeting - Yahoo Finance

Pulse Biosciences’ nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual Meeting Yahoo Finance

Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium - Business Wire

Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium Business Wire

Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX - Business Wire

Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX Business Wire

FDA IDE approval — Pulse Biosciences' nPulse to present early AF data at EACTS Oct 8-11 - Stock Titan

FDA IDE approval — Pulse Biosciences' nPulse to present early AF data at EACTS Oct 8-11 Stock Titan

The CellFX Percutaneous Electrode System for Nanosecond Pulsed Field Ablation - Mary Ann Liebert, Inc.

The CellFX Percutaneous Electrode System for Nanosecond Pulsed Field Ablation Mary Ann Liebert, Inc.

Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association - Yahoo Finance

Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association Yahoo Finance

Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System - Business Wire

Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System Business Wire

Discoveries in Travels from Nanovolts to Kilovolts - Mary Ann Liebert, Inc.

Discoveries in Travels from Nanovolts to Kilovolts Mary Ann Liebert, Inc.

Multicenter, prospective feasibility study of Nano-Pulse Stimulation™ technology for the treatment of both nodular and superficial low-risk basal cell carcinoma - Frontiers

Multicenter, prospective feasibility study of Nano-Pulse Stimulation™ technology for the treatment of both nodular and superficial low-risk basal cell carcinoma Frontiers

Pulse Biosciences Announces Collaboration with CardioNXT for nsPFA First-in-Human Atrial Fibrillation Study - Business Wire

Pulse Biosciences Announces Collaboration with CardioNXT for nsPFA First-in-Human Atrial Fibrillation Study Business Wire

Safety and effectiveness of nano-pulse stimulation™ technology to treat acne vulgaris of the back - Wiley Online Library

Safety and effectiveness of nano-pulse stimulation™ technology to treat acne vulgaris of the back Wiley Online Library

Pulse Biosciences Announces Start of Controlled Launch of the CellFX System® - Business Wire

Pulse Biosciences Announces Start of Controlled Launch of the CellFX System® Business Wire

Nano-Pulse Stimulation Induces Changes in the Intracellular Organelles in Rat Liver Tumors Treated In Situ - Wiley Online Library

Nano-Pulse Stimulation Induces Changes in the Intracellular Organelles in Rat Liver Tumors Treated In Situ Wiley Online Library

Top Pulse Biosciences, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant